{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:17:51Z","timestamp":1793783871438,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T00:00:00Z","timestamp":1755388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T00:00:00Z","timestamp":1755388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-15747-6","type":"journal-article","created":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T12:00:40Z","timestamp":1755432040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparing quality of life methadone and buprenorphine for opioid substitution treatment in Iran"],"prefix":"10.1038","volume":"15","author":[{"given":"Ahmad","family":"Nemati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amene","family":"Raouf-Rahmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosein","family":"Serhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Reza","family":"Mashreghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maliheh","family":"DadgarMoghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakime Ghadiri","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Talebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Niroumand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,17]]},"reference":[{"issue":"1","key":"15747_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","volume":"6","author":"J Strang","year":"2020","unstructured":"Strang, J. et al. Opioid use disorder. Nat. Reviews Disease Primers. 6(1), 3 (2020).","journal-title":"Nat. Reviews Disease Primers"},{"issue":"1","key":"15747_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1037\/ser0000607","volume":"20","author":"RR MacLean","year":"2023","unstructured":"MacLean, R. R., Sofuoglu, M., Stefanovics, E. & Rosenheck, R. Opioid use disorder with chronic pain increases disease burden and service use. Psychol. Serv. 20(1), 157 (2023).","journal-title":"Psychol. Serv."},{"issue":"1","key":"15747_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42399-024-01716-z","volume":"6","author":"H Zamani Moghadam","year":"2024","unstructured":"Zamani Moghadam, H. et al. Trend of blood glucose level alteration during the first day of hospitalization due to acute Tramadol poisoning. SN Compr. Clin. Med. 6(1), 1\u20138 (2024).","journal-title":"SN Compr. Clin. Med."},{"key":"15747_CR4","doi-asserted-by":"crossref","unstructured":"Ellis, J. D., Dunn, K. E. & Huhn, A. S. Harm reduction for opioid use disorder: strategies and outcome metrics. Am. J. Psychiatry (2024).","DOI":"10.1176\/appi.ajp.20230918"},{"issue":"2","key":"15747_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","volume":"23","author":"HS Connery","year":"2015","unstructured":"Connery, H. S. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv. Rev. Psychiatry. 23(2), 63\u201375 (2015).","journal-title":"Harv. Rev. Psychiatry"},{"issue":"01","key":"15747_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/0976-3147.91934","volume":"3","author":"PJ Whelan","year":"2012","unstructured":"Whelan, P. J. & Remski, K. Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. J. Neurosciences Rural Pract. 3(01), 45\u201350 (2012).","journal-title":"J. Neurosciences Rural Pract."},{"issue":"6","key":"15747_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","volume":"10","author":"L Degenhardt","year":"2023","unstructured":"Degenhardt, L. et al. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. Lancet Psychiatry. 10(6), 386\u2013402 (2023).","journal-title":"Lancet Psychiatry"},{"key":"15747_CR8","unstructured":"Group W, editor The development of the World Health Organization quality of life assessment instrument (the WHOQOL). In Quality of Life Assessment: International Perspectives: Proceedings of the Joint-Meeting Organized by the World Health Organization and the Fondation IPSEN in Paris, July 2\u20133, 1993. (Springer, 1994)."},{"key":"15747_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11205-008-9315-7","volume":"90","author":"J De Maeyer","year":"2009","unstructured":"De Maeyer, J., Vanderplasschen, W. & Broekaert, E. Exploratory study on drug users\u2019 perspectives on quality of life: more than health-related quality of life? Soc. Indic. Res. 90, 107\u2013126 (2009).","journal-title":"Soc. Indic. Res."},{"issue":"5","key":"15747_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.drugpo.2010.01.010","volume":"21","author":"J De Maeyer","year":"2010","unstructured":"De Maeyer, J., Vanderplasschen, W. & Broekaert, E. Quality of life among opiate-dependent individuals: A review of the literature. Int. J. Drug Policy. 21(5), 364\u2013380 (2010).","journal-title":"Int. J. Drug Policy"},{"key":"15747_CR11","doi-asserted-by":"publisher","first-page":"109445","DOI":"10.1016\/j.drugalcdep.2022.109445","volume":"235","author":"OK Golan","year":"2022","unstructured":"Golan, O. K. et al. Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder. Drug Alcohol Depend. 235, 109445 (2022).","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"15747_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s40359-023-01164-9","volume":"11","author":"M Dehghan","year":"2023","unstructured":"Dehghan, M. et al. The relationship between beliefs in substance craving and quality of life among narcotics anonymous: a cross-sectional study in southeastern Iran. BMC Psychol. 11(1), 126 (2023).","journal-title":"BMC Psychol."},{"issue":"4","key":"15747_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/npr2.12402","volume":"43","author":"HM Chang","year":"2023","unstructured":"Chang, H. M., Huang, M. C., Fang, S. C. & Lin, S. K. Quality of life and associated factors of heroin-dependent patients receiving methadone and buprenorphine maintenance treatment. Neuropsychopharmacol. Rep. 43(4), 607\u2013615 (2023).","journal-title":"Neuropsychopharmacol. Rep."},{"issue":"5","key":"15747_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1046\/j.1360-0443.2003.00352.x","volume":"98","author":"SM Giacomuzzi","year":"2003","unstructured":"Giacomuzzi, S. M. et al. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction 98(5), 693\u2013702 (2003).","journal-title":"Addiction"},{"issue":"5","key":"15747_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1159\/000514192","volume":"27","author":"SPE Guillery","year":"2021","unstructured":"Guillery, S. P. E. et al. Quality of life in opioid replacement therapy: a naturalistic cross-sectional comparison of methadone\/levomethadone, buprenorphine, and diamorphine patients. Eur. Addict. Res. 27(5), 371\u2013380 (2021).","journal-title":"Eur. Addict. Res."},{"issue":"1","key":"15747_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jsat.2006.11.009","volume":"33","author":"I Maremmani","year":"2007","unstructured":"Maremmani, I., Pani, P. P., Pacini, M. & Perugi, G. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J. Subst. Abuse Treat. 33(1), 91\u201398 (2007).","journal-title":"J. Subst. Abuse Treat."},{"issue":"1","key":"15747_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1100\/tsw.2005.52","volume":"5","author":"SM Giacomuzzi","year":"2005","unstructured":"Giacomuzzi, S. M., Ertl, M., Kemmler, G., Riemer, Y. & Vigl, A. Sublingual buprenorphine and methadone maintenance treatment: a three-year follow\u2010up of quality of life assessment. Sci. World J. 5(1), 452\u2013468 (2005).","journal-title":"Sci. World J."},{"key":"15747_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.drugalcdep.2013.10.011","volume":"134","author":"JP Feelemyer","year":"2014","unstructured":"Feelemyer, J. P., Des Jarlais, D. C., Arasteh, K., Phillips, B. W. & Hagan, H. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review. Drug Alcohol Depend. 134, 251\u2013258 (2014).","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"15747_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/00952990701523698","volume":"33","author":"AM Ponizovsky","year":"2007","unstructured":"Ponizovsky, A. M. & Grinshpoon, A. Quality of life among heroin users on buprenorphine versus methadone maintenance. Am. J. Drug Alcohol Abus. 33(5), 631\u2013642 (2007).","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"4","key":"15747_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/01.adt.0000210078.99735.27","volume":"5","author":"S O\u2019Brien","year":"2006","unstructured":"O\u2019Brien, S. et al. Maintenance pharmacotherapy for opioid dependence and SF-36 health status: A comparison with general population norms and other chronic disorders. Addict. Disorders their Treat. 5(4), 155\u2013164 (2006).","journal-title":"Addict. Disorders their Treat."},{"issue":"2","key":"15747_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.34172\/hpp.2021.29","volume":"11","author":"H Rafiemanesh","year":"2021","unstructured":"Rafiemanesh, H. et al. Opium dependence and the potential impact of changes in treatment coverage level: A dynamic modeling study. Health Promotion Perspect. 11(2), 240 (2021).","journal-title":"Health Promotion Perspect."},{"issue":"10","key":"15747_CR22","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1111\/add.13453","volume":"111","author":"M Amin-Esmaeili","year":"2016","unstructured":"Amin-Esmaeili, M. et al. Epidemiology of illicit drug use disorders in iran: prevalence, correlates, comorbidity and service utilization results from the Iranian mental health survey. Addiction 111(10), 1836\u20131847 (2016).","journal-title":"Addiction"},{"key":"15747_CR23","doi-asserted-by":"publisher","first-page":"108871","DOI":"10.1016\/j.drugalcdep.2021.108871","volume":"226","author":"M Ansari","year":"2021","unstructured":"Ansari, M. et al. Buprenorphine abuse and health risks in iran: A systematic review. Drug Alcohol Depend. 226, 108871 (2021).","journal-title":"Drug Alcohol Depend."},{"key":"15747_CR24","doi-asserted-by":"publisher","first-page":"103529","DOI":"10.1016\/j.drugpo.2021.103529","volume":"100","author":"Y Rostam-Abadi","year":"2022","unstructured":"Rostam-Abadi, Y. et al. Public health risks associated with methadone in iran: A systematic review and meta-analysis. Int. J. Drug Policy. 100, 103529 (2022).","journal-title":"Int. J. Drug Policy"},{"key":"15747_CR25","doi-asserted-by":"crossref","unstructured":"Aghayan, S., Amiri, M., Chaman, R. & Khosravi, A. Quality of life in methadone maintenance treated patients in Iran. Int. J. High. Risk Behav. Addict. 4(4). (2015).","DOI":"10.5812\/ijhrba.22275"},{"issue":"7","key":"15747_CR26","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3109\/10826084.2010.517726","volume":"47","author":"R Noori","year":"2012","unstructured":"Noori, R., Narenjiha, H., Aghabakhshi, H., Habibi, G. & Khoshkrood Mansoori, B. Methadone maintenance therapy outcomes in Iran. Subst. Use Misuse. 47(7), 767\u2013773 (2012).","journal-title":"Subst. Use Misuse"},{"issue":"3","key":"15747_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0740-5472(02)00222-2","volume":"22","author":"J Ahmadi","year":"2002","unstructured":"Ahmadi, J. Buprenorphine maintenance treatment of heroin dependence: the first experience from Iran. J. Subst. Abuse Treat. 22(3), 157\u2013159 (2002).","journal-title":"J. Subst. Abuse Treat."},{"issue":"5","key":"15747_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2298\/VSP150710227M","volume":"74","author":"M Marinkovi\u0107","year":"2017","unstructured":"Marinkovi\u0107, M., \u0110or\u0111evi\u0107, J. L., Miljkovi\u0107, S., Milojkovi\u0107, B. & Janji\u0107, V. Quality of life of treated opiate addicts in the methadone maintenance program and those treated with buprenorphine. Vojnosanit. Pregl. 74(5), 435\u2013444 (2017).","journal-title":"Vojnosanit. Pregl."},{"key":"15747_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6963-8-61","volume":"8","author":"S Nedjat","year":"2008","unstructured":"Nedjat, S., Montazeri, A., Holakouie, K., Mohammad, K. & Majdzadeh, R. Psychometric properties of the Iranian interview-administered version of the world health organization\u2019s quality of life questionnaire (WHOQOL-BREF): a population-based study. BMC Health Serv. Res. 8, 1\u20137 (2008).","journal-title":"BMC Health Serv. Res."},{"key":"15747_CR30","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1007\/s11136-017-1674-6","volume":"26","author":"L Strada","year":"2017","unstructured":"Strada, L. et al. Measuring quality of life in opioid-dependent people: a systematic review of assessment instruments. Qual. Life Res. 26, 3187\u20133200 (2017).","journal-title":"Qual. Life Res."},{"key":"15747_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1023\/B:QURE.0000018486.91360.00","volume":"13","author":"S Sm","year":"2004","unstructured":"Sm, S. The world health organization\u2019s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual. Life Res. 13, 299\u2013310 (2004).","journal-title":"Qual. Life Res."},{"issue":"10","key":"15747_CR32","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1046\/j.1360-0443.2001.961014337.x","volume":"96","author":"K Barrau","year":"2001","unstructured":"Barrau, K. et al. Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction 96(10), 1433\u20131441 (2001).","journal-title":"Addiction"},{"issue":"2","key":"15747_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.drugalcdep.2013.07.018","volume":"133","author":"J Maas","year":"2013","unstructured":"Maas, J., Barton, G., Maskrey, V., Pinto, H. & Holland, R. Economic evaluation: A comparison of methadone versus buprenorphine for opiate substitution treatment. Drug Alcohol Depend. 133(2), 494\u2013501 (2013).","journal-title":"Drug Alcohol Depend."},{"key":"15747_CR34","doi-asserted-by":"crossref","unstructured":"Aas, C. F. et al. Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway. Substance abuse treatment, prevention, and policy. 15, 1\u201312 (2020).","DOI":"10.1186\/s13011-020-00286-2"},{"key":"15747_CR35","doi-asserted-by":"crossref","unstructured":"Bratu, M. L. et al. Evaluating the aspects of quality of life in individuals with substance use disorder: A systematic review based on the WHOQOL questionnaire. J. Multidisciplinary Healthc. 4265\u20134278. (2023).","DOI":"10.2147\/JMDH.S440764"},{"key":"15747_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.drugalcdep.2013.10.011","volume":"134","author":"JP Feelemyer","year":"2014","unstructured":"Feelemyer, J. P., Jarlais, D. C. D., Arasteh, K., Phillips, B. W. & Hagan, H. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review. Drug Alcohol Depend. 134, 251\u2013258 (2014).","journal-title":"Drug Alcohol Depend."},{"key":"15747_CR37","doi-asserted-by":"crossref","unstructured":"Marinkovic, M., Djordjevic-Jovanovic, L., Miljkovi\u0107, S., Milojkovic, B. & Janjic, V. Quality of life of treated opiate addicts in the methadone maintenance program and those treated with buprenorphine. (2017).","DOI":"10.2298\/VSP150710227M"},{"key":"15747_CR38","doi-asserted-by":"publisher","first-page":"108996","DOI":"10.1016\/j.drugalcdep.2021.108996","volume":"228","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: results from a multisite trial of buprenorphine-naloxone and methadone. Drug Alcohol Depend. 228, 108996 (2021).","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"15747_CR39","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/j.1743-6109.2007.00702.x","volume":"5","author":"R Hallinan","year":"2008","unstructured":"Hallinan, R. et al. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J. Sex. Med. 5(3), 684\u2013692 (2008).","journal-title":"J. Sex. Med."},{"issue":"8","key":"15747_CR40","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.3390\/ijms19082410","volume":"19","author":"G Serafini","year":"2018","unstructured":"Serafini, G. et al. The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review. Int. J. Mol. Sci. 19(8), 2410 (2018).","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"15747_CR41","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/ajad.12644","volume":"26","author":"M Litz","year":"2017","unstructured":"Litz, M. & Leslie, D. The impact of mental health comorbidities on adherence to buprenorphine: A claims based analysis. Am. J. Addictions. 26(8), 859\u2013863 (2017).","journal-title":"Am. J. Addictions"},{"issue":"5","key":"15747_CR42","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/add.13259","volume":"111","author":"A Mokri","year":"2016","unstructured":"Mokri, A., Chawarski, M. C., Taherinakhost, H. & Schottenfeld, R. S. Medical treatments for opioid use disorder in iran: a randomized, double-blind placebo\u2010controlled comparison of buprenorphine\/naloxone and naltrexone maintenance treatment. Addiction 111(5), 874\u2013882 (2016).","journal-title":"Addiction"},{"issue":"3","key":"15747_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/medicina43030029","volume":"43","author":"\u017d Padaiga","year":"2007","unstructured":"Padaiga, \u017d., Subata, E. & Vanagas, G. Outpatient methadone maintenance treatment program quality of life and health of opioid-dependent persons in Lithuania. Medicina 43(3), 235 (2007).","journal-title":"Medicina"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15747-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15747-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15747-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:27:24Z","timestamp":1757392044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15747-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,17]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15747"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15747-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,17]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to ethical guidelines and received approval from the Ethics Committee of Mashhad University of Medical Sciences (Ethical code: IR.MUMS.MEDICAL.REC.1398.122), and all methods were performed in accordance with the relevant guidelines and regulations. All participants in the study gave informed consent, and their personal details were kept confidential through coding.The study included a provision for intervention: if a patient\u2019s QOL was assessed as low following the interview and questionnaire completion by a researcher, they were referred to a collaborating psychiatrist for appropriate interventions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30107"}}